Royalty Pharma Plc Stock Today
| RPRX Stock | USD 31.95 0.01 0.03% |
Performance12 of 100
| Odds Of DistressLess than 9
|
Royalty Pharma is trading at 31.95 as of the 29th of January 2025; that is 0.03 percent increase since the beginning of the trading day. The stock's open price was 31.94. Royalty Pharma has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 1st of October 2024 and ending today, the 29th of January 2025. Click here to learn more.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. The company was founded in 1996 and is based in New York, New York. Royalty Pharma is traded on NASDAQ Exchange in the United States.. The company has 444.3 M outstanding shares of which 16.63 M shares are at this time shorted by private and institutional investors with about 4.45 trading days to cover. More on Royalty Pharma Plc
Moving against Royalty Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Royalty Stock Highlights
Royalty Pharma Plc (RPRX) is traded on NASDAQ Exchange in USA. It is located in 110 East 59th Street, New York, NY, United States, 10022 and employs 16 people. Royalty Pharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 18.82 B. Royalty Pharma Plc conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 444.3 M outstanding shares of which 16.63 M shares are at this time shorted by private and institutional investors with about 4.45 trading days to cover.
Royalty Pharma Plc currently holds about 1.47 B in cash with 2.99 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34.
Check Royalty Pharma Probability Of Bankruptcy
Ownership AllocationThe majority of Royalty Pharma Plc outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Royalty Pharma Plc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Royalty Pharma. Please pay attention to any change in the institutional holdings of Royalty Pharma Plc as this could imply that something significant has changed or is about to change at the company.
Check Royalty Ownership Details
Royalty Pharma Plc Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Royalty Pharma market risk premium is the additional return an investor will receive from holding Royalty Pharma long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1381 | |||
| Jensen Alpha | 0.318 | |||
| Total Risk Alpha | 0.1259 | |||
| Sortino Ratio | 0.1669 |
Royalty Stock Against Markets
Royalty Pharma Corporate Management
| Eric Schneider | Senior Officer | Profile | |
| George Lloyd | Executive Officer | Profile | |
| Marshall MD | Executive Investments | Profile | |
| Sandy Balkin | Senior Analytics | Profile | |
| Sara Klymkowsky | Senior Investments | Profile | |
| Ashwin MD | Executive Investments | Profile |
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.